Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension

• Published in: Scandinavian journal of clinical and laboratory investigation Vol. 79; no. 4; pp. 268 - 275
• Main Authors: Kriechbaum, Steffen D., Wiedenroth, Christoph B., Hesse, Maura L., Ajnwojner, Ruth, Keller, Till, Sebastian Wolter, Jan, Haas, Moritz, Roller, Fritz C., Breithecker, Andreas, Rieth, Andreas J., Guth, Stefan, Rolf, Andreas, Hamm, Christian W., Mayer, Eckhard, Liebetrau, Christoph
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 19-05-2019
• Subjects: Angioplasty, Balloon; balloon pulmonary angioplasty; Biomarkers - metabolism; Cardiology; Chronic Disease; chronic thromboembolic pulmonary hypertension; Female; Hemodynamics; Humans; Hypertension, Pulmonary - physiopathology; Hypertension, Pulmonary - surgery; kidney disease; kidney function; Kidney Function Tests; Male; Middle Aged; Natriuretic Peptide, Brain - metabolism; Peptide Fragments - metabolism; Renal Insufficiency, Chronic - physiopathology; Renal Insufficiency, Chronic - surgery; Thromboembolism - physiopathology; Thromboembolism - surgery; troponins and cardiac biomarkers; chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; kidney disease; kidney function; Cardiology; troponins and cardiac biomarkers
• ISSN: 0036-5513; 1502-7686
• DOI: 10.1080/00365513.2019.1601765

Balloon pulmonary angioplasty (BPA), for chronic thromboembolic pulmonary hypertension, improves pulmonary and systemic hemodynamics. The kidney might benefit from this effect. However, staged BPA therapy comes along with repetitive administration of contrast agent. This study examined the overall effect of BPA therapy on renal function. This study included consecutive patients who underwent BPA treatment and completed a 6-month follow-up between March 2014 and March 2017. Biomarker-based evaluation of renal function was performed at baseline, consecutively prior to and after each BPA and at 6-month follow-up. The 51 patients underwent an average of 5 (±2) BPA sessions. In this course, patients received 133 (±48; 21-300) mL of contrast agent per session and 691 (±24; 240-1410) mL during the whole sequence. Acute kidney injury occurred after 6 (2.3%) procedures. The creatinine [80.1 (IQR 67.8-96.8) µmol/L vs. 77.4 (IQR 66.9-91.5) µmol/L, p = .02] and urea level [13.7 (IQR10.7-16.6) mmol/L vs. 12.5 (IQR 10.0-15.5) mmol/L, p = .02] decreased from baseline to the 6-month follow-up. The estimated glomerular filtration rate (eGFR) [79 (IQR 59-94) mL/min/m
2
vs. 79.6 (IQR 67.1-95.0) mL/min/m
2
, p = .11] did not change. The Chronic kidney disease (CKD) stages at baseline were: G1:15; G2:23; G3a:10; G3b:2; G4:1; G5:0. Among patients with a CKD-stage ≥2, analysis revealed an increase of eGFR, decrease of creatinine and urea from baseline to 6-month follow-up. Among those patients, the baseline-CKD-stage improved in 14 (41.2%) patients. BPA therapy improves pulmonary and systemic hemodynamics, with positive effects on renal function. Repetitive administration of contrast agent seems not to be harmful regarding renal function.